These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38042220)

  • 1. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
    Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
    Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses
    Ghorbaninezhad F; Masoumi J; Bakhshivand M; Baghbanzadeh A; Mokhtarzadeh A; Kazemi T; Aghebati-Maleki L; Shotorbani SS; Jafarlou M; Brunetti O; Santarpia M; Baradaran B; Silvestris N
    Front Immunol; 2022; 13():931316. PubMed ID: 35979362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint.
    Ahangar NK; Khalaj-Kondori M; Alizadeh N; Mokhtarzadeh A; Baghbanzadeh A; Shadbad MA; Dolatkhah K; Baradaran B
    Gene; 2023 Mar; 855():147086. PubMed ID: 36535461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
    Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():676181. PubMed ID: 34093577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.
    Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z
    Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions.
    Grubczak K; Kretowska-Grunwald A; Groth D; Poplawska I; Eljaszewicz A; Bolkun L; Starosz A; Holl JM; Mysliwiec M; Kruszewska J; Wojtukiewicz MZ; Moniuszko M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study.
    Shekari N; Shanehbandi D; Baghbani E; Safaei S; Masoumi J; Baradaran B; Jalali SA
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; ():. PubMed ID: 39365310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 silencing could promote anti-tumor effects in hepatocellular.
    Mardi A; Alizadeh M; Abdolalizadeh AS; Baghbanzadeh A; Baradaran B; Aghebaqti-Maleki A; Sandoghchian Shotorbani S; Movloudi M; Aghebati-Maleki L
    Med Oncol; 2024 Jul; 41(8):193. PubMed ID: 38955918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma.
    Sorkhabi AD; Sarkesh A; Fotouhi A; Saeedi H; Aghebati-Maleki L
    IUBMB Life; 2022 Sep; 74(9):908-917. PubMed ID: 35638098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
    Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
    Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
    Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The suppressive effect of co-inhibiting
    Liang L; Ge K; Zhang F; Ge Y
    Cell Mol Biol Lett; 2018; 23():58. PubMed ID: 30564277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VSIG-3 as a ligand of VISTA inhibits human T-cell function.
    Wang J; Wu G; Manick B; Hernandez V; Renelt M; Erickson C; Guan J; Singh R; Rollins S; Solorz A; Bi M; Li J; Grabowski D; Dirkx J; Tracy C; Stuart T; Ellinghuysen C; Desmond D; Foster C; Kalabokis V
    Immunology; 2019 Jan; 156(1):74-85. PubMed ID: 30220083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.